# U.S. Patent 4,529,596: Claim Scope, Clopidogrel Coverage, Expiration and Patent Landscape
U.S. Patent No. 4,529,596 is an early Sanofi patent covering a broad class of tetrahydrothieno[3,2-c]pyridine derivatives with platelet-aggregation-inhibiting and antithrombotic activity. Its claims encompass methyl 2-chlorophenyl derivatives corresponding to the racemic form of clopidogrel, together with related esters, amides, acids, salts, enantiomers, pharmaceutical compositions and therapeutic methods. The patent issued July 16, 1985, and its original U.S. patent term expired in 2002. It does not create a current U.S. barrier to generic clopidogrel entry. [1]
What drug and chemical class does U.S. Patent 4,529,596 cover?
The patent covers substituted tetrahydrothieno[3,2-c]pyridine compounds. The commercially important compound within the claimed class is clopidogrel, an antiplatelet agent marketed principally as clopidogrel bisulfate under the Plavix brand.
Clopidogrel is generally identified as:
- Methyl (+)-(S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate
- The active S enantiomer of the methyl 2-chlorophenyl ester
- A thienopyridine prodrug that undergoes metabolic activation
- A P2Y12 platelet-receptor inhibitor
The structural terminology in the patent uses “4,5,6,7-tetrahydro-thieno(3,2-c)-5-pyridyl,” while modern nomenclature often describes the same fused-ring system as 6,7-dihydrothieno[3,2-c]pyridine. The nomenclature difference does not, by itself, alter the chemical subject matter.
What does claim 1 of U.S. Patent 4,529,596 cover?
Claim 1 is the principal Markush claim. It covers a genus of compounds defined by two major variable groups: the substituent designated Y and the substituent designated X.
Y-variable scope
Y may be:
- Hydroxyl, producing the corresponding carboxylic acid;
- An OR group, where R is a straight or branched lower alkyl group, producing an ester; or
- An amide group, where R1 and R2 may be hydrogen or lower alkyl groups.
The amide option also covers cyclic amines in which R1 and R2 form a heterocycle with the nitrogen atom. The expressly listed heterocycles are:
- Pyrrolidino
- Piperidino
- Morpholino
- Piperazino
- N-lower-alkyl piperazino
- N-benzyl piperazino
This gives claim 1 coverage across acids, alkyl esters and a defined set of amides.
X-variable scope
X may be:
- Hydrogen
- A halogen
- A lower alkyl radical
The claim therefore reaches unsubstituted phenyl compounds and phenyl compounds bearing halogen or lower-alkyl substitution. The expressly claimed examples include ortho-chloro and ortho-fluoro analogues.
Stereochemical and salt scope
Claim 1 includes:
- Both enantiomers
- A mixture of enantiomers, including the racemate
- Pharmaceutically acceptable acid-addition salts for ester and amide embodiments
- Mineral-base salts for acid embodiments
The claim is materially broader than a claim limited to clopidogrel bisulfate. It covers the underlying ester free base, its enantiomers, racemic mixtures and specified salt forms.
Which specific compounds are claimed in claims 2 through 7?
Claims 2 through 7 identify specific compounds within the broader genus.
| Claim |
Compound |
Commercial relevance |
| 2 |
Methyl alpha-(4,5,6,7-tetrahydro-thieno[3,2-c]-5-pyridyl)-ortho-chlorophenylacetate |
Corresponds to the clopidogrel racemate at the core-structure level |
| 3 |
Methyl alpha-(4,5,6,7-tetrahydro-thieno[3,2-c]-5-pyridyl)phenylacetate |
Unsubstituted phenyl analogue |
| 4 |
Methyl alpha-(4,5,6,7-tetrahydro-thieno[3,2-c]-5-pyridyl)-ortho-fluorophenylacetate |
Ortho-fluoro analogue |
| 5 |
Isopropyl alpha-(4,5,6,7-tetrahydro-thieno[3,2-c]-5-pyridyl)-ortho-chlorophenylacetate |
Isopropyl ester analogue |
| 6 |
Ethyl alpha-(4,5,6,7-tetrahydro-thieno[3,2-c]-5-pyridyl)-ortho-chlorophenylacetate |
Ethyl ester analogue |
| 7 |
N,N-dimethyl alpha-(4,5,6,7-tetrahydro-thieno[3,2-c]-5-pyridyl)-ortho-chlorophenylacetamide |
Dimethylamide analogue |
Claim 2 is the most commercially significant. It identifies the methyl ester with an ortho-chlorophenyl group, the structure associated with clopidogrel before resolution into its active enantiomer and conversion to the bisulfate salt.
The claim language supplied does not impose a single absolute configuration on claim 2. Claim 1 expressly includes both enantiomeric forms and their mixtures. Accordingly, the patent's original structure is broader than a later patent directed specifically to the pharmacologically preferred S enantiomer.
Does U.S. Patent 4,529,596 cover clopidogrel bisulfate?
It covers the underlying clopidogrel ester and, through the salt language in claim 1, can reach pharmaceutically acceptable acid-addition salts of the claimed ester. The patent is not limited to bisulfate, however.
The commercially used product is clopidogrel bisulfate, also called clopidogrel hydrogen sulfate. Later patent protection focused more specifically on:
- The optically active S enantiomer;
- The hydrogen sulfate salt;
- Pharmaceutical compositions containing the selected enantiomeric salt;
- Manufacturing and solid-state characteristics associated with the commercial product.
The distinction matters because a broad genus patent such as No. 4,529,596 can cover the chemical family while later patents protect a narrower, commercially optimized form.
What do claims 8 through 10 protect?
Claims 8 through 10 cover pharmaceutical compositions containing a claimed compound and a pharmaceutically acceptable carrier.
Claim 8
Claim 8 covers a therapeutic composition having:
- Platelet-aggregation-inhibiting activity; and
- Antithrombotic activity.
The composition must contain an effective amount of a claim 1 compound, one of its salts, one of its enantiomers or a mixture of enantiomers, together with a pharmaceutically acceptable carrier.
Claim 9
Claim 9 narrows the composition to unit dosage form.
Claim 10
Claim 10 further specifies a unit dosage containing 0.10 gram to 1.00 gram of active ingredient.
That dosage range is unusually high relative to modern commercial clopidogrel dosing, which is generally expressed in milligrams. The claim is still relevant to claim construction because it defines an express quantitative limitation, but it does not represent the typical commercial Plavix dose.
What do claims 11 and 12 protect?
Claims 11 and 12 are method-of-treatment claims.
| Claim |
Protected activity |
| 11 |
Inhibiting platelet aggregation in mammals |
| 12 |
Treating or inhibiting thrombosis in mammals |
Both claims require administering an effective amount of a composition containing a claim 1 compound and a suitable pharmaceutically acceptable carrier.
The method claims are functional and therapeutic. They do not depend on a particular disease label, dosage schedule, route of administration or named patient subgroup in the supplied text. Their practical scope is therefore tied to use of a covered compound for platelet aggregation or thrombosis.
Under modern U.S. patent law, method claims require infringement by practicing the claimed treatment method. Product sales may create indirect infringement issues, but liability would depend on evidence of induced or contributory infringement and the status of the patent at the relevant time.
When did U.S. Patent 4,529,596 expire?
U.S. Patent No. 4,529,596 issued July 16, 1985. Because it is an early U.S. patent governed by the pre-1995 patent-term rule, its term was generally 17 years from grant. The patent therefore expired in July 2002, absent an unusual adjustment or extension. [1]
| Event |
Date |
| U.S. patent issue |
July 16, 1985 |
| Ordinary 17-year term from grant |
July 16, 2002 |
| Current enforceability |
Expired |
| Current generic-entry barrier from this patent |
None |
The patent predates the Hatch-Waxman framework's modern Orange Book litigation structure and predates the 20-year-from-priority-date term applicable to later-filed U.S. applications.
What was the relationship between this patent and later clopidogrel patents?
The commercial clopidogrel estate developed through follow-on patents directed to narrower subject matter.
Enantiomer patents
Later Sanofi patents addressed optically active thienopyridine derivatives, including the S enantiomer corresponding to clopidogrel. These patents narrowed the subject matter from the racemic or broad Markush disclosure toward the active enantiomer used commercially.
Bisulfate-salt patents
Separate patents addressed the hydrogen sulfate salt of the S enantiomer. These patents were commercially important because Plavix was marketed as clopidogrel bisulfate rather than as an undifferentiated racemic ester.
Composition and formulation patents
The later estate included claims directed to pharmaceutical compositions and dosage forms. These claims were narrower than the original chemical genus and were evaluated separately in abbreviated new drug application litigation.
Manufacturing and process patents
Process patents may have covered:
- Resolution of the enantiomers;
- Preparation of clopidogrel intermediates;
- Formation of the bisulfate salt;
- Crystallization and isolation steps;
- Control of impurities and stereochemical purity.
Process patents can create manufacturing risk even after a compound patent expires, but they do not prevent production if the relevant process claims have expired or can be designed around.
What was the Orange Book status of clopidogrel patents?
Clopidogrel was subject to the Hatch-Waxman framework through later listed patents associated with Plavix. The FDA Orange Book identifies patents submitted by the NDA holder and approved product information for drug products. [2]
The commercially significant protection did not rest solely on U.S. Patent No. 4,529,596. Later patents covering the active enantiomer and bisulfate salt were more directly connected to the marketed product.
The Orange Book framework allowed generic applicants to make Paragraph IV certifications against listed patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. Filing such a certification can trigger patent litigation and a 30-month stay of FDA approval under the statutory conditions. [3]
Because the principal clopidogrel patents have expired, current generic applications generally do not face a live Orange Book patent barrier from the original patent family.
Which companies challenged clopidogrel patents?
Clopidogrel patent litigation involved multiple generic-drug companies, including Apotex and other ANDA applicants. The most commercially important dispute involved Apotex and the Plavix companies, including Sanofi and Bristol-Myers Squibb.
The litigation and settlement activity addressed the later patent estate rather than the already expired 1985 patent. Generic companies challenged the validity, enforceability or infringement of later patents directed to the active enantiomer and bisulfate salt.
The settlement structure permitted generic entry before the latest asserted patent expiry. Apotex launched clopidogrel products in the United States in 2012, subject to the terms of the parties' settlement and subsequent commercial arrangements. [4]
What was the commercial impact of clopidogrel patent expiry?
Plavix was one of the highest-revenue cardiovascular products before generic entry. Sanofi reported multibillion-dollar annual sales for Plavix before the U.S. loss of exclusivity. Bristol-Myers Squibb also reported substantial alliance revenue from the product. [5]
| Commercial issue |
Effect of patent expiry |
| Brand pricing |
Significant downward pressure |
| Generic competition |
Multiple ANDA-approved suppliers |
| Prescribing |
Rapid substitution toward generic clopidogrel |
| Revenue |
Sharp erosion after U.S. generic launch |
| Patent value of No. 4,529,596 today |
Historical rather than blocking |
The economic exposure was concentrated in the later active-enantiomer and salt patents. No. 4,529,596 had already expired for roughly a decade before broad U.S. generic competition became commercially visible.
How strong was the patent estate for clopidogrel?
The estate was strong during its commercial life because it used layered protection:
- An early broad chemical genus;
- Specific compounds, including the ortho-chloro methyl ester;
- Later protection for the active S enantiomer;
- Hydrogen sulfate salt claims;
- Composition and method claims;
- Process and manufacturing claims.
The original patent's strengths were its breadth and early priority. Its weaknesses were age, lack of a commercial-product-specific limitation in many claims and eventual expiration in 2002.
For present-day freedom-to-operate analysis, the original patent has no blocking strength. The relevant risks would instead arise from any surviving jurisdiction-specific process, formulation, polymorph, combination or regulatory exclusivity rights. For U.S. clopidogrel, those barriers have largely ended.
Are biosimilar risks relevant to clopidogrel?
No. Clopidogrel is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic-drug applicants filing ANDAs under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not biosimilar applicants filing under the Public Health Service Act. [3]
The principal regulatory issues are bioequivalence, pharmaceutical equivalence, salt form, stereochemical composition, labeling and approval of the relevant dosage strengths.
What geographic coverage did U.S. Patent 4,529,596 provide?
The patent provided rights only in the United States. Equivalent foreign applications and patents would have required separate analysis by jurisdiction, with different filing dates, claim scope, term rules and litigation histories.
A U.S. expiration did not automatically determine the status of corresponding rights in:
- Europe;
- Canada;
- Japan;
- Australia;
- Emerging markets;
- Countries where patent applications were abandoned or never granted.
The U.S. patent's current status is therefore distinct from the international patent landscape. For U.S. commercial planning, however, No. 4,529,596 is expired and cannot independently block manufacture, sale or use.
Key Takeaways
- U.S. Patent No. 4,529,596 covers a broad class of tetrahydrothieno[3,2-c]pyridine antiplatelet compounds.
- Claim 1 includes acids, alkyl esters, specified amides, salts, enantiomers and racemic mixtures.
- Claim 2 covers the methyl ortho-chlorophenyl ester corresponding to the clopidogrel core structure.
- Claims 8 through 10 cover pharmaceutical compositions and unit-dose forms.
- Claims 11 and 12 cover platelet-aggregation and thrombosis treatment methods.
- The patent issued July 16, 1985, and expired in July 2002 under the pre-1995 17-year patent term.
- Later patents covering the S enantiomer and clopidogrel bisulfate were more important to Plavix exclusivity.
- Paragraph IV litigation and generic settlements focused on later clopidogrel patents, not on a live 4,529,596 right.
- Clopidogrel is a small molecule, so biosimilar law is not applicable.
- No. 4,529,596 presents no current U.S. generic-entry barrier.
FAQs
Does U.S. Patent 4,529,596 claim the S enantiomer of clopidogrel?
Yes, claim 1 expressly includes both enantiomeric forms and their mixtures. The patent is not limited to the S enantiomer used commercially.
Does the patent claim clopidogrel bisulfate specifically?
It can reach acid-addition salts of covered ester compounds, but it does not appear from the supplied claims to require bisulfate as the specific counterion. Later patents addressed the commercial hydrogen sulfate salt more directly.
Could a generic company have launched clopidogrel after July 2002?
Expiration of No. 4,529,596 removed that patent as a barrier, but later patents covering the active enantiomer and bisulfate salt could still delay or condition generic entry.
Does claim 10 cover ordinary Plavix tablets?
Claim 10 requires 0.10 gram to 1.00 gram of active ingredient per unit. That range is materially higher than conventional clopidogrel tablet strengths, which are generally measured in milligrams. Coverage would depend on the actual formulation and claim construction.
Is a clopidogrel manufacturing process still exposed to this patent?
No. An expired composition patent cannot block a process solely because the process makes the claimed compound. A separate, unexpired process patent would be required to create current U.S. manufacturing risk.
References
- U.S. Patent No. 4,529,596, Thienopyridine derivatives, process for their preparation and pharmaceutical compositions containing them, issued July 16, 1985. U.S. Patent and Trademark Office. https://patents.google.com/patent/US4529596
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly purified synthetic peptides. https://www.fda.gov
- Sanofi-Aventis U.S. LLC v. Apotex Inc., related clopidogrel ANDA litigation and settlement proceedings, U.S. District Court filings.
- Sanofi. (2012). Annual report 2012. https://www.sanofi.com_en/investors/financial-results-and-events/annual-reports
